Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.
Abbott Laboratories (NYSE: ABT) is a globally recognized American multinational company headquartered in Abbott Park, Illinois. Founded in 1888, Abbott has established itself as a leader in medical devices and health care. The company manufactures and markets a wide range of products, including cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.
Abbott's product portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays along with point-of-care diagnostic equipment. Approximately 60% of Abbott’s sales are derived from markets outside the United States, underlining its global reach and influence.
Recently, Abbott introduced the PROTALITY™ brand, a high-protein nutrition shake aimed at supporting weight loss while preserving muscle mass. This innovation reflects Abbott's commitment to addressing global health challenges such as obesity and muscle health. The company also continues to make strides in medical technology with advancements like the TriClip™ system for tricuspid valve repair, and the FreeStyle Libre continuous glucose monitoring systems, which have set new standards in diabetes management.
Abbott is not only focused on innovative product development but also on strategic partnerships and sustainability. The extension of their partnership with the Real Madrid Foundation, aimed at reducing childhood malnutrition and promoting healthy habits, is a testament to their commitment to global health improvements.
Financially, Abbott has demonstrated robust performance, as evidenced by its consistent dividend payouts and its inclusion in the S&P 500 Dividend Aristocrats Index. The company reported strong Q1 2024 results with significant growth in their core business segments, further supported by successful product launches and clinical innovations.
Abbott’s mission to help people live more fully at all stages of life drives their development of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. With a workforce of over 114,000 employees serving people in over 160 countries, Abbott continues to set benchmarks in the healthcare industry.
Abbott (NYSE: ABT) is set to release its fourth-quarter 2022 financial results on January 25, 2023, prior to market opening. Following the announcement, a live webcast of the earnings conference call will take place at 8 a.m. CT (9 a.m. ET), accessible via Abbott's Investor Relations website. Abbott is a leading global healthcare firm with a diverse portfolio, including diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries with a workforce of approximately 113,000 employees.
Abbott has announced that its FreeStyle Libre 3 sensor is now integrated with the mylife™ Loop automated insulin delivery (AID) system, marking a significant advancement in diabetes management. This innovative system, available in Germany and expanding to other European countries in 2023, automates insulin delivery based on real-time glucose data, simplifying diabetes care. Currently, this solution is not available in the United States. With over 4.5 million users, Abbott aims to enhance glucose control, helping many regain lost healthy years due to inadequate diabetes management.
Abbott (NYSE: ABT) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 11 a.m. Central time. The presentation will be led by Robert B. Ford, chairman and CEO. A live webcast will be available on Abbott's Investor Relations website, with an archived version accessible later the same day. Abbott is a leading global healthcare company committed to enhancing lives through its diverse portfolio, impacting over 160 countries with approximately 113,000 employees.
Abbott has received FDA approval for its Eterna spinal cord stimulation (SCS) system, designed to treat chronic pain. This device is the smallest rechargeable spinal cord stimulator on the market, requiring as few as five recharges annually, significantly optimizing patient comfort. Eterna employs Abbott's BurstDR stimulation technology, which has been clinically proven to alleviate pain more effectively than traditional methods. With over 50 million Americans affected by chronic pain, Abbott aims to enhance healthcare delivery and improve patient outcomes through innovative solutions.
Abbott (NYSE: ABT) and the Brain Injury Association of America have co-founded Concussion Awareness Now, a coalition of nearly 20 advocacy groups aimed at increasing awareness about concussions. The initiative emphasizes the importance of diagnosis and treatment, with over half of individuals suspecting a concussion neglecting to seek care. Actress Rebel Wilson, who recently experienced a concussion, shares her story to support the cause. The coalition aims to change societal perceptions surrounding concussions and encourage proper medical attention.
Abbott (NYSE: ABT) announced an 8.5% increase in its quarterly dividend, raising it to 51 cents per share. This marks the company’s 51st consecutive year of dividend growth and the 396th consecutive quarterly dividend, to be paid on Feb. 15, 2023, to shareholders of record by Jan. 13, 2023. Abbott is recognized in the S&P 500 Dividend Aristocrats Index for consistent annual dividend increases over at least 25 years, reflecting its commitment to sustainable growth and shareholder returns.
Abbott (NYSE: ABT) has won three CES 2023 Innovation Awards from the Consumer Technology Association for its innovative health technologies. The awarded products include the Aveir VR Leadless Pacemaker, the Proclaim Plus SCS System, and the Alinity m Monkeypox PCR test. Abbott's achievements continue as the company was previously recognized for its FreeStyle Libre technology, named the best medical technology of the last 50 years by the Galien Foundation. This recognition underscores Abbott's commitment to advancing healthcare solutions globally.
Surmodics announced positive results from the 24-month follow-up of its TRANSCEND clinical trial at the VIVA conference in Las Vegas. The study involved 446 patients and compared the SurVeil DCB with the leading IN.PACT Admiral DCB. Results show that SurVeil achieved a primary patency rate of 70.8% versus 70.4% for IN.PACT, with comparable safety profiles. SurVeil uses a significantly lower dose of paclitaxel, which may enhance patient outcomes. Surmodics holds a partnership with Abbott (ABT) for commercialization upon FDA approval.
FAQ
What is the current stock price of Abbott Laboratories (ABT)?
What is the market cap of Abbott Laboratories (ABT)?
What does Abbott Laboratories specialize in?
What are some of Abbott’s recent product launches?
How much of Abbott’s sales are generated outside the United States?
What is Abbott’s PROTALITY™ brand?
How does Abbott support global health initiatives?
What is Abbott’s financial performance like?
How many employees does Abbott have?
Which continuous glucose monitoring system is Abbott known for?
What is Abbott's mission?
In how many countries does Abbott operate?
